105 results about "Anti biofilm" patented technology

There is disclosed a method for disrupting biofilm and for inhibiting biofilm formation in an aqueous environment that comprises contacting said environment with an effective amount of D-tagatose.

The present invention provides methods for preventing biofilm formation on a surface. The present invention also relates to anti-biofilm forming agents, to methods of producing and using them, and to anti-fouling coatings produced therefrom.

Disclosed herein are an anti-biofilm composition and a method to inhibit or prevent cell adhesion and/or biofilm formation by a microorganism, in which use of 1,2,3,4,6-penta-O-galloyl-D-glucopyranose (PGG) is involved therein.

The invention is directed to a method for detecting the presence of biofilm-forming microorganisms in a paper or board making process for determining the need of an anti-biofilm agent in the process. The method comprises the steps: (a) subjecting a sampler device in the process line for a period of time to enable said microorganisms to form a biofilm in situ in said process on the surface of the sampler, (b) optionally treating said formed biofilm in a solution of a test anti-biofilm agent for a period of time, then (c) contacting said biofilm with a liquid growth medium in a recession of a culturing device for a period of time, and (d) removing the growth solution from the recession of said device and detecting qualitatively and/or quantitatively the presence or absence of a biofilm adhered on the walls of the recession. An assembly kit is also provided.

The present invention provides compositions comprising an antibiofilm enzyme, a soluble β-N-acetylglucosaminidase similar to the dspB gene (DispersinB®), and an antimicrobial for preventing growth and proliferation of biofilm-embedded microorganisms in acute and chronic wounds, and methods of treatment. The invention further provides methods for preparing medical devices, and in particular, wound care devices using soluble β-N-acetylglucosaminidase based antimicrobial compositions.

The invention relates to a method of inhibiting the biofilm formation by thermophilic adhering microbes of paper and board machines on the surfaces of paper or board machines, and/or removing such biofilms from the said surfaces by adding to the circulation waters of the paper or board machines at least one pure substance isolated from a plant or at least one plant extract or a mixture thereof in such a concentration which is effective against thermophilic adhering microbes. The invention further relates to a method of determining the need of the addition of an anti-biofilm agent in paper and board manufacturing processes, and an assembly kit suitable for the same.

Compositions and methods, including novel homogeneous microparticulate suspensions, are described for treating acute wounds, chronic wounds and/or a wound or epithelial tissue surface that contains bacterial biofilm, including unexpected synergy between bismuth-thiol (BT) compounds and certain antibiotics, to provide topical formulations including antiseptic formulations, for management and promotion of wound healing and in particular infected wounds. Previously unpredicted antibacterial properties and anti-biofilm properties of disclosed BT compounds and BT compound-plus-antibiotic combinations are also described, including preferential efficacies of certain such compositions for treating gram-positive bacterial infections, and distinct preferential efficacies of certain such compositions for treating gram-negative bacterial infections.

Compositions and methods, including novel homogeneous microparticulate suspensions, are described for treating natural and artificial surfaces that contain bacterial biofilm, including unexpected synergy or enhancing effects between bismuth-thiol (BT) compounds and certain antibiotics, to provide formulations including antiseptic formulations. Previously unpredicted antibacterial properties and anti-biofilm properties of disclosed BT compounds and BT compound-plus-antibiotic combinations are also described, including preferential efficacies of certain such compositions for treating certain gram-positive bacterial infections, and distinct preferential efficacies of certain such compositions for treating certain gram-negative bacterial infections.

A biofilm resistant fluid handling system is provided having at least one structural component adapted to retain or deliver fluid. The at least one structural component is formed from a biofilm resistant material comprising polymeric resin and an inorganic carrier conjugated with a biocidal metal ion. When a surface of the at least one structural component is exposed to a continuous or intermittent aqueous solution environment the formation of active biofilm on the surface is prevented and planktonic bacteria in proximity of said surface is killed. Additionally, methods for extending the biocidal properties of a biofilm resistant fluid handling system are provided. One includes continuously or periodically introducing a biocidal metal ion into contents of the aqueous solution environment resulting in equilibrium of biocidal metal ion exchange between the biofilm resistant material of the handling system and the aqueous solution environment, Another includes affixing a solvent, comprising an inorganic carrier conjugated with a biocidal metal ion, to the surface of the fluid handling system.

An anti-biofilm catheter comprising a tubing configured to be disposed within a luminal system, wherein the tubing comes in contacting engagement with a blood flow within the luminal system in vivo. The catheter comprises a surface disposed over at least a portion of the tubing, wherein the surface comprises a surface profile having a skewness value of from about −0.01 to about −0.6 such that few or no components of the blood flow is capable of attaching themselves to the surface to encourage biofilm formation. The surface profile further comprises a kurtosis value of from about 2.7 to 3.3.

This invention is a diagnostic plate that can be used to select antibiotic combinations with efficacy against microorganisms growing as a biofilm. The plate allows growth of biofilm on a plurality of projections, and the subsequent simultaneous challenge of biofilms on all projections of the plate to independent concentrations and combinations of anti-biofilm agents. Resistance of microorganisms to antibiotics is higher when they grow as a biofilm, as compared to when they grow in a planktonic state which is usually used to determine their level of antibiotic sensitivity. Growth of microorganisms that slough off the biofilm in the anti-biofilm agent challenge determines the Minimum Inhibitory Concentration (MIC) which relates to sensitivity of the microorganisms in a planktonic state. Growth of any surviving microorganisms from the biofilm in a subsequent recovery step determines the Minimal Biofilm Eradication Concentration (MBEC) which relates to the sensitivity of the microorganisms growing as a biofilm. Enumeration of the surviving microorganisms in the recovery step determines the Minimum Biocidal Concentration (MBC).

The invention discloses a ZIF-8/carbon dot anti-biofilm composite nano material and a preparation method thereof. According to the method, a metal organic framework ZIF-8 is taken as a carrier, lysine carbon quantum dots are taken as an antibacterial agent, and the lysine carbon quantum dots are embedded into the ZIF-8 framework under the coordination action of nitrogen-containing groups on the surfaces of the lysine carbon quantum dots and zinc ions, so that the anti-biofilm composite nano material is prepared. Compared with single ZIF-8 and Lys-CD, the ZIF-8/carbon dot anti-biofilm composite nanomaterial prepared by the invention has the advantages that the anti-biofilm activity is obviously enhanced, meanwhile, the composite material is endowed with good biocompatibility by the Lys-CD, and the ZIF-8/carbon dot anti-biofilm composite nanomaterial has a wide application prospect in the field of anti-biofilms.

This invention is a diagnostic plate that can be used to select antibiotic combinations with efficacy against microorganisms growing as a biofilm. The plate allows growth of biofilm on a plurality of projections, and the subsequent simultaneous challenge of biofilms on all projections of the plate to independent concentrations and combinations of anti-biofilm agents. Resistance of microorganisms to antibiotics is higher when they grow as a biofilm, as compared to when they grow in a planktonic state which is usually used to determine their level of antibiotic sensitivity. Growth of microorganims that slough off the biofilm in the anti-biofilm agent challenge determines the Minimum Inhibitory Concentration (MIC) which relates to sensitivity of the microorganisms in a planktonic state. Growth of any surviving microorganims from the biofilm in a subsequent recovery step determines the Minimal Biofilm Eradication Concentration (MBEC) which relates to the sensitivity of the microorganisms growing as a biofilm. Enumeration of the surviving microorganims in the recovery step determines the Minimum Biocidal Concentration (MBC).

Disclosed herein is a novel antifungal compound, derivatives that are used to treat fungal infections. In a specific embodiment, the compound is a small molecule. In a specific embodiment, the compound described herein inhibits yeast to hypha transition under robust hyphal inducing conditions at lower concentration of the molecule. Also disclosed is a composition comprising the antifungal compound. In a specific embodiment, the composition is a pharmaceutical composition. Also disclosed is a method of treating and/or preventing fungal infection using the disclosed compound. The disclosed compound exhibits antifungal activity against wide range of fungal species at slightly higher concentrations. Antifungal compound disclosed herein is used as anti-biofilm agent against fungal infections.

The present invention provides non-peptide compounds of formula (I) wherein: X is —(C₁-C₈)allcyl-, aryl or -aryl(C₁-C₈)alkyl-; Y is —(C₁-C₈)alkyl- or absent; W is heteroaryl, (C₃-C₇)carbocycle or aryl, wherein any heteroaryl, (C₃-C₇)carbocycle or, aryl of W is optionally substituted with one or more (e.g. 1, 2, 3, 4 or 5) Z¹ groups; R¹ is (C₁-C₈)alkyl, (C₂-C₈)alkenyl, (C₂-C₈)alkynyl or aryl, wherein aryl is optionally substituted with one or more (e.g. 1, 2, 3, 4 or 5) groups selected from (C₁-C₈)alkyl, (C₂-C₈)alkenyl, (C₂-C₈)alkynyl, (C₃-C₇)carbocycle, halo(C₁-C₃)alkyl, —CN, NO₂, halogen, —OR_a, —SR_a, —S(O)₂NR_bR_c, —NR_bR_c, —NR_aCOR_d, —C(O)R_a, —C(O)OR_a, and —C(O)NR_bR_c; R² is (C₁-C₈)alkyl, (C₂-C₈)alkenyl, (C₂-C₈)Jalkynyl or aryl, wherein aryl is optionally substituted with one or more (e.g. 1, 2, 3, 4 or 5) groups selected from (C₁-C₈)alkyl, (C₂-C₈)alkenyl, (C₂-C₈)alkynyl, (C₃-C₇)carbocycle, halo(C₁-C₃)alkyl, —CN, NO₂, halogen, —OR_e, —SR_e, —S(O)₂NR_fR_g, —NR_fR_g—NR_eCOR_h, —C(O)R_e, —C(O)OR_e and —C(O)NR_fR_g; I that mimic the streptococcal; SspB Adherence Region (BAR) and function as inhibitors of P. gingivalis adherence to streptococci. The invention also provides methods of making and using the inhibitors.